Aims-To analyse the latent membrane protein-1 (LMP-1) gene in a series of patients with Epstein-Barr virus (EBV) positive LMP expressing ordinary and HIV associated Hodgkin's disease to detect possible genetic alterations and particularly the existence of deletions near the 3' end of the gene.
Methods-Expression of the EBV LMP-1 was assessed using immunohistochemistry in 186 cases ofHodgkin's disease and 31 cases of HIV associated Hodgkin's disease. Genomic DNA was extracted from frozen lymph node biopsy specimens from 25 cases of Hodgkin's disease and 11 of HIV associated Hodgkin's disease, all of whom expressed the LMP-1 protein within diagnostic Hodgkin and Reed-Sternberg (HRS) cells, and amplified by polymerase chain reaction (PCR) using primers specific for the different LMP-1 regions. Results-LMP-1 expression was observed in 106 of 186 Hodgkin's disease cases and in all 31 HIV associated Hodgkin's disease cases. Molecular analysis of the LMP-1 gene showed a high degree of genetic heterogeneity in the carboxy-terminal domain compared with the prototype B95-8 EBV strain, specially in the patients with HIV associated Hodgkin's disease. Variation in the size of the repeated region was found in 17 of 25 Hodgkin's disease and nine of 11 EBV typing was performed by amplifying DNA from the EBV 3C nuclear antigen (EBNA-3C). Amplification of type A EBV DNA gave rise to a 153 bp fragment and type B EBV DNAs to a 246 bp product. Primers and PCR conditions are described elsewhere. 26 The LMP-1 gene was amplified using different primer pairs specific for the N terminal, transmembrane and C terminal domains (for detailed information about PCR conditions and primer sequences see 27). Each PCR product (5 gl) was electrophoresed on a 6% polyacrylamide gel for one hour at 150 volts at room temperature to check the amount, specificity, and size of the PCR product. DNA extracted from the B95-8 and AG876 cell lines was used to control for types A and B, respectively, EBV. The AG876 LMP-1 gene contains the same 30 
